Journal of Clinical Oncology
Articles in this Issue
Tumor evolution following treatment with sacituzumab govitecan for metastatic breast cancer: A proteomic analysis.
e13006 Background: Sacituzumab Govitecan (SG) is a Trop2-targeting antibody drug conjugate (ADC) approved for the treatmen...
IBI363 (TAK-928) plus chemotherapy as first-line (1L) treatment for advanced non–small cell lung cancer (NSCLC).
8586 Background: IBI363 is a first-in-class, PD-1/IL-2 α-bias bispecific antibody...
CDH6-high gastric cancers as exhibitors of a reproducible vascular–stromal, immune-excluded tumor microenvironment.
e15179 Background: Cadherin-6 (CDH6) is a developmental adhesion molecule aberrantly expressed in subsets of gastric cance...
Temporal trends and disparities in gallbladder cancer mortality: A U.S. population-based study.
e16175 Background: Gallbladder cancer (GBC) is a relatively uncommon malignancy with one of the most unfavorable prognoses...
Timing of biomarker testing and associated clinical outcomes in ovarian cancer patients: A retrospective study.
e17574 Background: In ovarian cancer (OC) patients, biomarker testing can inform treatment decisions and thereby guide opt...
Recurrence patterns and site-level survival in the previous phase III study of IL13-PE38QQR: Implications for drug distribution variability.
2017 Background: Interleukin-13–Pseudomonas Exotoxin A (IL13-PE38QQR) is a targeted cytotoxic fusion protein directed agai...
Neoadjuvant chemotherapy with/without PD-1i in locally advanced laryngeal/hypopharyngeal cancer: A multicentered retrospective study.
6085 Background: The efficacy of adding programmed death-1 (PD-1) inhibitors to neoadjuvant chemotherapy (NACT) for improv...
Biomarker-driven assessment of immunochemotherapy with or without fruquintinib as first-line treatment for advanced gastric/GEJ adenocarcinoma: Initial clinical results and subgroup analysis from the MGC-FLORA study.
4063 Background: The MGC-FLORA study is a prospective biomarker-exploratory trial primarily designed to identify predictiv...
Neoadjuvant systemic chemotherapy combined with camrelizumab (CAM) and apatinib (APA) for BCLC stage A/B hepatocellular carcinoma (HCC) beyond Milan criteria: An interim analysis of a phase 2 trial.
e16283 Background: Patients(Pts) in BCLC stage A/B HCC beyond Milan criteria have a high recurrence rate after radical sur...
Secondary genomic alterations and clinical outcomes in myxoid liposarcoma: A multi-institutional analysis.
11580 Background: Myxoid liposarcoma (MLS) is defined by DDIT3 rearrangements. The...
Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer by stratified subgroups.
1005 Background: In the phase 3 HER2CLIMB-05 study (NCT05132582), TUC + maintenance HP demonstrated a statistically signif...
Real-world outcomes and safety of FGFR inhibitors in intrahepatic cholangiocarcinoma: A TriNetX analysis.
e16186 Background: Intrahepatic cholangiocarcinoma (iCCA) is a rare and aggressive malignancy associated with poor prognos...
Efficacy and safety of HLX43 (an anti–PD-L1 ADC) in previously treated recurrent/metastatic nasopharyngeal carcinoma: A multicenter, randomized phase 2 study.
6060 Background: Treatment options are limited and clinical outcomes remain unsatisfactory for patients with recurrent/met...
A retrospective analysis of neoadjuvant chemotherapy (NAC) versus upfront surgery (US) in resectable pancreatic adenocarcinoma at a large tertiary care center.
e16448 Background: Resectable pancreatic adenocarcinoma (rPAC) has a notoriously high mortality worldwide, even in cases o...
Association between circulating tumor DNA and local tumor regrowth and distant metastasis during nonoperative management in stage I–III rectal cancer.
3615 Background: During nonoperative management (NOM) for rectal cancer after a clinical complete response (cCR) or near-C...
Association of neutrophil-to-lymphocyte ratio and thrombotic events in US veterans with polycythemia vera.
6578 Background: Neutrophil-to-lymphocyte ratio (NLR) is a novel predictor of thrombosis in patients with Polycythemia Ver...
Utilization patterns and disparities in supportive oncology services for patients with stage IV non-small cell lung cancer.
e20649 Background: Supportive oncology (SO) services, including palliative care, social work, and dietitian support, are e...
The efficacy and safety of 177Lu-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC): Single-institution, real-world data.
e17040 Background: Lutetium Lu 177 vipivotide tetraxetan is a radiopharmaceutical that had received FDA approval in March...
Expression analysis of molecules targeting regulatory T-cells in patients with oral squamous cell carcinoma.
e14508 Background: Immune checkpoint blockade is an important cancer treatment, but its therapeutic efficacy varies among...
Safety and efficacy of QLC5508 (MHB088C) in heavily-treated patients with metastatic castration-resistant prostate cancer: Updated data from a phase 1/2 trial.
5046 Background: QLC5508 (MHB088C), a novel B7-H3-targeted antibody-drug conjugate with high cell-binding activity and int...
PSMA PET/CT–guided intensification of salvage radiotherapy versus conventional planning for biochemical recurrence after radical prostatectomy: A GRADE-assessed systematic review and meta-analysis.
e17145 Background: Salvage radiotherapy (SRT) is the standard treatment for biochemical recurrence (BCR) after radical pro...
T-cell prolymphocytic leukemia: A review of induction therapies.
e18617 Background: T cell prolymphocytic leukemia (T-PLL) is an aggressive neoplasm composed of mature T cells, with a med...
Ultra-sensitive whole-genome sequencing–based molecular residual disease detection in resectable sarcoma in MONSTAR-SCREEN-3.
11544 Background: Circulating tumor DNA (ctDNA)–based molecular residual disease (MRD) detection has shown strong prognost...
Automated eligibility screening for adjuvant CDK4/6 inhibitors in high-risk HR+/HER2− early breast cancer using natural language processing.
e23303 Background: While CDK4/6 inhibitors (CDK4/6i) have transformed the treatment landscape for high-risk, HR+/HER2- ear...
Artificial intelligence and machine learning in relapsed/refractory multiple myeloma: A systematic review.
e19500 Background: Relapsed/refractory multiple myeloma (RRMM) remains incurable with heterogeneous outcomes. Trad...